Effect of hepatocyte growth factor and angiotensin II on rat cardiomyocyte hypertrophy

Ai-Lan Chen1, Cai-Wen Ou, Zhao-Chu He

  • 1Department of Cardiology, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Insights

Hepatocyte growth factor (HGF) and Angiotensin II (Ang II) both promote cardiomyocyte hypertrophy. Their combined use significantly amplifies this effect, revealing a novel mechanism in heart cell growth.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Cell Biology

Background:

  • Angiotensin II (Ang II) is a key factor in cardiomyocyte hypertrophy.
  • The synergistic effects of hepatocyte growth factor (HGF) and Ang II on cardiomyocytes remain largely unexplored.

Purpose of the Study:

  • To investigate the individual effect of HGF on cardiomyocyte hypertrophy.
  • To determine the combined impact of HGF and Ang II on cardiomyocyte hypertrophy.

Main Methods:

  • Primary cardiomyocytes were isolated from neonatal rat hearts and cultured in vitro.
  • Cells were treated with Ang II, HGF, or a combination of both for 24, 48, and 72 hours.
  • Protein synthesis, gene expression (β-myosin heavy chain, atrial natriuretic factor), and cell size were assessed.

Main Results:

  • Both Ang II and HGF individually promoted cardiomyocyte hypertrophy.
  • The combination of Ang II and HGF demonstrated a significant, amplified pro-hypertrophy effect on cardiomyocytes.
  • Increased protein synthesis and fetal gene expression patterns were observed.

Conclusions:

  • HGF alone can induce cardiomyocyte hypertrophy.
  • A novel, combined pro-hypertrophy effect of HGF and Ang II on cardiomyocytes has been identified.
  • This finding offers new insights into the molecular mechanisms of cardiac remodeling.

Related Concept Videos

Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...